aniracetam has been researched along with Disease Models, Animal in 12 studies
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The anxiolytic effects of aniracetam have not been proven in animals despite its clinical usefulness for post-stroke anxiety." | 7.71 | Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. ( Kurasawa, M; Nakamura, K, 2001) |
| "The anxiolytic effects of aniracetam have not been proven in animals despite its clinical usefulness for post-stroke anxiety." | 3.71 | Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. ( Kurasawa, M; Nakamura, K, 2001) |
| "The pyrrolidinone derivative aniracetam given orally immediately after acquisition of an inhibitory avoidance response reproducibly ameliorated scopolamine-induced amnesia in female rats in an extensive series of test sessions conducted over a 1-year period." | 3.69 | Aniracetam reverses memory impairment in rats. ( Jenck, F; Martin, JR; Moreau, JL, 1995) |
| "Aniracetam pre-treatment significantly increased alcohol-reinforced responses relative to vehicle treatment." | 1.39 | Enhanced AMPA receptor activity increases operant alcohol self-administration and cue-induced reinstatement. ( Besheer, J; Cannady, R; Durant, B; Fisher, KR; Hodge, CW, 2013) |
| "Aniracetam was administered to 1-month-old rats, demonstrating a prolonged (2 months) therapeutic effect, observed in rats aged 3 months." | 1.31 | Can nootropic drugs be effective against the impact of ethanol teratogenicity on cognitive performance? ( Vaglenova, J; Vesselinov Petkov, V, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (25.00) | 18.2507 |
| 2000's | 5 (41.67) | 29.6817 |
| 2010's | 3 (25.00) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Solinski, HJ | 1 |
| Dranchak, P | 1 |
| Oliphant, E | 1 |
| Gu, X | 1 |
| Earnest, TW | 1 |
| Braisted, J | 1 |
| Inglese, J | 1 |
| Hoon, MA | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Huang, HC | 1 |
| Zhong, RL | 1 |
| Cao, P | 1 |
| Wang, CR | 1 |
| Yang, DG | 1 |
| Milot, MR | 1 |
| Plamondon, H | 1 |
| Cannady, R | 1 |
| Fisher, KR | 1 |
| Durant, B | 1 |
| Besheer, J | 1 |
| Hodge, CW | 1 |
| Groom, AJ | 1 |
| Smith, T | 1 |
| Turski, L | 1 |
| Vaglenova, J | 2 |
| Pandiella, N | 1 |
| Wijayawardhane, N | 1 |
| Vaithianathan, T | 1 |
| Birru, S | 1 |
| Breese, C | 1 |
| Suppiramaniam, V | 1 |
| Randal, C | 1 |
| Martin, JR | 1 |
| Moreau, JL | 1 |
| Jenck, F | 1 |
| Himori, N | 1 |
| Suzuki, T | 1 |
| Ueno, K | 1 |
| Vesselinov Petkov, V | 1 |
| Nakamura, K | 1 |
| Kurasawa, M | 1 |
| Tanabe, S | 1 |
| Ikeda, Y | 1 |
| Sugawa, M | 1 |
| Iwasaki, T | 1 |
12 other studies available for aniracetam and Disease Models, Animal
| Article | Year |
|---|---|
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S | 2019 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
[Effects of Goutengsan on model of Alzheimer dementia in rats by AlCl3].
Topics: Aluminum Chloride; Aluminum Compounds; Alzheimer Disease; Animals; Body Weight; Brain; Chlorides; Di | 2008 |
How right is the righting reflex? The risk of false positives in neuroprotection studies using behavioral measures to certify forebrain ischemia.
Topics: Animals; Cell Survival; Disease Models, Animal; Dose-Response Relationship, Drug; Male; Memory Disor | 2010 |
Enhanced AMPA receptor activity increases operant alcohol self-administration and cue-induced reinstatement.
Topics: Alcohol Drinking; Alcoholism; Analysis of Variance; Animals; Conditioning, Operant; Cues; Disease Mo | 2013 |
Multiple sclerosis and glutamate.
Topics: Animals; Brain Stem; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Excitatory | 2003 |
Aniracetam reversed learning and memory deficits following prenatal ethanol exposure by modulating functions of synaptic AMPA receptors.
Topics: Animals; Animals, Newborn; Avoidance Learning; Behavior, Animal; Body Weight; Disease Models, Animal | 2008 |
Aniracetam reverses memory impairment in rats.
Topics: Administration, Oral; Amnesia; Animals; Avoidance Learning; Disease Models, Animal; Dose-Response Re | 1995 |
Aniracetam, a pyrrolidinone-type cognition enhancer, attenuates the hydroxyl free radical formation in the brain of mice with brain ischaemia.
Topics: Animals; Brain; Brain Ischemia; Chromatography, High Pressure Liquid; Disease Models, Animal; Dopami | 1995 |
Can nootropic drugs be effective against the impact of ethanol teratogenicity on cognitive performance?
Topics: Alcohol-Induced Disorders, Nervous System; Animals; Disease Models, Animal; Female; Learning Disabil | 2001 |
Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Bro | 2001 |
[Effects of BY-1949 on three kinds of experimental amnesia in rodents].
Topics: Amnesia; Animals; Avoidance Learning; Dibenzoxazepines; Disease Models, Animal; Male; Mice; Pyrrolid | 1990 |